Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer

Niclosamide, an anthelmintic drug approved by the US Food and Drug Administration against cestodes, is used to treat tapeworm infection. In this study, we show that niclosamide can potentially inhibit signal transducer and activator of transcription 3 (STAT3) in colon cancer cell lines. Combined inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Lingyi, Zheng, Hailun, Hu, Wanle, Zhou, Bin, Dai, Xuanxuan, Zhang, Yi, Liu, Zhiguo, Wu, Xiaoping, Zhao, Chengguang, Liang, Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370071/
https://www.ncbi.nlm.nih.gov/pubmed/28367059
http://dx.doi.org/10.2147/OTT.S129449
Descripción
Sumario:Niclosamide, an anthelmintic drug approved by the US Food and Drug Administration against cestodes, is used to treat tapeworm infection. In this study, we show that niclosamide can potentially inhibit signal transducer and activator of transcription 3 (STAT3) in colon cancer cell lines. Combined inhibition of epidermal growth factor receptor and STAT3 by erlotinib and niclosamide synergistically induces apoptosis and antiproliferation in colon cancer cell lines. Our findings suggest that erlotinib and niclosamide combination provides an effective therapeutic approach to improving the prognosis of colon cancer.

Ejemplares similares